{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:08Z","timestamp":1791357848673,"version":"4.3.1"},"reference-count":59,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Daprodustat (GSK1278863) is a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor in development for treatment of anemia of chronic kidney disease. Daprodustat\u2019s biological activity simulates components of the natural response to hypoxia; inhibition of PHDs results in HIF stabilization and modulation of HIF-controlled gene products, including erythropoietin. The carcinogenic potential of daprodustat was evaluated in 2-year carcinogenicity studies in Sprague-Dawley rats and CD-1 mice, where once-daily doses were administered. The mouse study also included evaluation of daprodustat\u2019s 3 major circulating human metabolites. There were no neoplastic findings that were considered treatment related in either study. Exaggerated pharmacology resulted in significantly increased red cell mass and subsequent multiorgan congestion and secondary non-neoplastic effects in both species, similar to those observed in chronic toxicity studies. In rats, these included aortic thrombosis and an exacerbation of spontaneous rodent cardiomyopathy, which contributed to a statistically significant decrease in survival in high-dose males (group terminated in week 94). Survival was not impacted in mice at any dose. Systemic exposures (area under the plasma concentration\u2013time curve) to daprodustat at the high doses in rats and mice exceed predicted maximal human clinical exposure by \u2265143-fold. These results suggest that daprodustat and metabolites do not pose a carcinogenic risk at clinical doses.<\/jats:p>","DOI":"10.1177\/0192623319880445","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:07:32Z","timestamp":1571789252000},"page":"362-378","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor"],"prefix":"10.1177","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-2130","authenticated-orcid":false,"given":"David F.","family":"Adams","sequence":"first","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Watkins","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Durette","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Goulet","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Senneville, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Debien","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4608-5543","authenticated-orcid":false,"given":"Kendall S.","family":"Frazier","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nac\u00e9ra","family":"Mellal","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Senneville, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfu","family":"Chen","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Thomas","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erding","family":"Hu","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline R&D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"bibr1-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242503"},{"key":"bibr2-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.23.10553"},{"key":"bibr3-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.13.5680"},{"key":"bibr4-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.12.12.5447"},{"key":"bibr5-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314427"},{"key":"bibr6-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.01.021"},{"key":"bibr7-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.12.5510"},{"key":"bibr8-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.1.72"},{"key":"bibr9-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1038\/35107085"},{"key":"bibr10-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1126\/science.1852076"},{"key":"bibr11-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31750"},{"key":"bibr12-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1007\/s10059-010-0067-2"},{"key":"bibr13-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2012.02.006"},{"key":"bibr14-0192623319880445","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.102319"},{"key":"bibr15-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1038\/20459"},{"key":"bibr16-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002740200"},{"key":"bibr17-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00507-4"},{"key":"bibr18-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059817"},{"key":"bibr19-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059796"},{"key":"bibr20-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1139\/o02-115"},{"key":"bibr21-0192623319880445","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2013-0134"},{"key":"bibr22-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.441"},{"key":"bibr23-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2013.251470"},{"key":"bibr24-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz013"},{"key":"bibr25-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.11.057"},{"key":"bibr26-0192623319880445","volume-title":"Poster presented at: American College of Toxicology 31st Annual Meeting; November 7-10","author":"Beck J","year":"2010"},{"key":"bibr27-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817737232"},{"key":"bibr28-0192623319880445","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"1996"},{"key":"bibr29-0192623319880445","unstructured":"SAS Institute Inc. SAS\/STAT\u00ae 9.2 and 9.4 User\u2019s Guides. 2009. https:\/\/support.sas.com\/documentation\/cdl\/en\/statug\/63033\/HTML\/default\/viewer.htm#titlepage.htm. Accessed March 18, 2019."},{"issue":"2","key":"bibr30-0192623319880445","first-page":"311","author":"Peto R","year":"1980","journal-title":"IARC Monogr Eval Carcinog Risk Chem Hum Suppl"},{"key":"bibr31-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1080\/10543409808835216"},{"key":"bibr32-0192623319880445","unstructured":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration. FDA draft guidance for industry: statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. 2001. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm079272.pdf. Accessed March 18, 2019."},{"key":"bibr33-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1080\/019262390908371"},{"key":"bibr34-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1080\/03610738208258390"},{"key":"bibr35-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313477255"},{"key":"bibr36-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/0192623309356452"},{"key":"bibr37-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/50.5.1243"},{"key":"bibr38-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/019262338801600305"},{"key":"bibr39-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-010-6239-7"},{"key":"bibr40-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140534"},{"key":"bibr41-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1080\/01480540701873186"},{"key":"bibr42-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313486317"},{"key":"bibr43-0192623319880445","unstructured":"MIRCERA. EPAR-Scientific Discussion, EMEA. 2007. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/mircera-epar-scientific-discussion_en.pdf. Accessed March 15, 2019."},{"key":"bibr44-0192623319880445","unstructured":"Omontys (peginesatide). SBA-Pharmacology Review(s). FDA, Center for Drug Evaluation and Research (CDER). 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202799Orig1s000PharmR.pdf. Accessed March 15, 2019."},{"key":"bibr45-0192623319880445","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.4.383"},{"key":"bibr46-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(88)90226-2"},{"key":"bibr47-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/0047-6374(83)90084-2"},{"key":"bibr48-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/B978-044452771-4\/50008-0"},{"issue":"3","key":"bibr49-0192623319880445","first-page":"1S","volume":"29","author":"Berridge BR","year":"2016","journal-title":"Toxicol Pathol"},{"key":"bibr50-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315570340"},{"key":"bibr51-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1201\/b13783-15"},{"key":"bibr52-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00778.x"},{"key":"bibr53-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00469.2006"},{"key":"bibr54-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1161\/hy09t1.096249"},{"key":"bibr55-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2016.02.088"},{"key":"bibr56-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313486318"},{"key":"bibr57-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010818-021637"},{"key":"bibr58-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.03.008"},{"key":"bibr59-0192623319880445","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3183"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623319880445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623319880445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623319880445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:40:47Z","timestamp":1777653647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623319880445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1177\/0192623319880445"],"URL":"https:\/\/doi.org\/10.1177\/0192623319880445","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]}}}